Just bought DEPO..

quote:

---

pharmaceutical company focused on the development and commercialization of differentiated products that are based on oral drug delivery technologies. Depomed has developed two commercial products: GLUMETZA (metformin hydrochloride extended release tablets), which is a once-daily treatment for adults with type 2 diabetes that it commercializes in the United States with Santarus, Inc. (Santarus). ProQuin XR (ciprofloxacin hydrochloride extended release tablets), which is a once-daily treatment for uncomplicated urinary tract infections that Depomed commercializes in the United States with Watson Pharma (Watson).


The Company has two product candidates in Phase III clinical trials. In March 2008, Depomed initiated a Phase III clinical trial for DM-1796, a release formulation of gabapentin for the treatment of postherpetic neuralgia that Depomed have licensed to Solvay Pharmaceuticals, Inc. In September and October 2008, the Company initiated Breeze one and Breeze two, its Phase III clinical trials for DM-5689, a release formulation of gabapentin for the treatment of menopausal hot flashes. In February 2009, the Company completed enrollment of its Breeze one trial. The Company’s product pipeline include DM-5689 (formerly known as Gabapentin GR) for Menopausal Hot Flashes, DM-1796 (formerly known as Gabapentin GR) for Postherpetic Neuralgia, DM-3458 for Gastroesophageal Reflux Disease, DM-1992 for Parkinson's Disease, GLUMETZA and ProquinXR.


DM-1796 (formerly known as Gabapentin GR)


DM-1796 is the Company’s internally developed, release formulation of the compound gabapentin. Gabapentin is marketed by Pfizer Inc. for adjunctive therapy for epileptic seizures and postherpetic pain under the trade name Neurontin. It is also marketed by a number of other companies as a generic, immediate release drug. In November 2008, the Company entered into an Exclusive License Agreement with Solvay Pharmaceuticals, Inc. granting Solvay exclusive rights to develop and commercialize DM-1796 in the United States, Canada and Mexico for pain indications.


GLUMETZA


The 500-milligram strength of GLUMETZA is Depomed’s internally developed once-daily metformin product for type 2 diabetes. The United States Food & Drug Administration (FDA) approved GLUMETZA for marketing in the United States in June 2005. Depomed reacquired the United States rights to GLUMETZA from Biovail in December 2005. In June 2006, it entered into a promotion arrangement with King Pharmaceuticals related to GLUMETZA, under which the Company and King Pharmaceuticals jointly commercialize GLUMETZA in the United States. GLUMETZA was launched in the United States in September 2006. In October 2007, the Company terminated its promotion agreement with King related to GLUMETZA. In July 2008, the Company entered into a promotion agreement with Santarus granting Santarus exclusive rights to promote GLUMETZA in the United States. In connection with the restructuring of Depomed’s GLUMETZA agreements with Biovail in December 2005, it acquired a United States license to 1000-milligram strength of GLUMETZA utilizing Biovail drug delivery technology. In December 2007, the FDA approved the 1000 milligram formulation for marketing in the United States. The 500 milligram GLUMETZA has also been approved for marketing in Canada, where it is marketed by Biovail.


ProQuin XR


Depomed developed ProQuin XR, and the FDA approved it for marketing in the United States in May 2005. Esprit Pharma licensed marketing rights to ProQuin XR in the United States in July 2005, and launched the product in the United States in November 2005. The Company terminated its agreement with Esprit in July 2007 related to Proquin XR and relaunched Proquin XR with Watson in September 2007.


The Company competes with Bristol-Myers Squibb's, Glucophage XR, Sciele Pharma's Fortamet, Sciele Pharma, Barr Pharmaceuticals, Inc., ANDRX Corporation, Mylan Laboratories, Inc., Teva Pharmaceutical Industries, Ltd., Takeda Actos, GlaxoSmithKline Avandia, Pfizer Glucotrol, Merck’s Januvia and Schering-Plough Corporation.

---